Gold Nanoparticles Rewire Inflammatory Signals in Cells Carrying a Cancer-Linked JAK2 Mutation
Tiny gold particles carrying genetic targeting molecules have produced a striking two-stage response in leukemia-like cells, briefly quieting key immune alarm systems before triggering a delayed surge in inflammatory signaling. The findings, reported by researchers at Istanbul University in the journal Immunogenetics, point to a possible way of manipulating the chronic inflammation associated with myeloproliferative neoplasms, a group of blood cancers driven in part by abnormal growth of myeloid cells. But the work remains an early laboratory study: the experiments were conducted in cultured cell lines, not in patients or animals, and the nanoparticles’ effects were highly dependent on cell type, genetic background and exposure time.
The experimental system focused on the widely studied JAK2V617F mutation. JAK2 is an enzyme that normally transmits signals from cytokine receptors to the cell nucleus, helping regulate blood-cell production. The V617F mutation changes a single DNA base, producing a permanently active version of the enzyme. Instead of responding only when instructed by external growth signals, mutant JAK2 can continuously stimulate pathways that promote cell survival and proliferation. The mutation is found in many cases of polycythemia vera and in a substantial fraction of essential thrombocythemia and myelofibrosis, disorders in which excessive blood-cell production and persistent inflammation can contribute to clotting, bone-marrow scarring and disease progression.
The researchers explored whether spherical gold nanoparticles could be used to interfere with this abnormal biology while also altering the cells’ response to genetic material. Each particle was about 13 nanometres across before it was coated with strands of DNA-like oligonucleotides, producing a final construct roughly 25 nanometres in diameter. The attached sequences were designed to pair with messenger RNA encoding either normal JAK2 or the JAK2V617F mutant. Pairing an oligonucleotide with its complementary messenger RNA can destabilize the transcript or hinder its translation, potentially reducing production of the corresponding protein. Gold nanoparticles are useful carriers because dense layers of nucleic acids on their surfaces can improve stability and promote uptake through endocytosis, the process by which cells engulf material into membrane-bound compartments.
The team treated three human cell lines with the constructs at a concentration of 200 picomolar and measured their responses over intervals ranging from 30 minutes to 72 hours. HEL cells carry two copies of JAK2V617F and resemble aspects of polycythemia vera. SET2 cells carry one mutant copy and are used as a model related to essential thrombocythemia. K562 cells, included as a comparison, lack JAK2V617F and instead carry the BCR-ABL fusion associated with chronic myeloid leukemia. The researchers also used nanoparticles bearing scrambled oligonucleotide sequences that were not designed to match any cellular transcript. Gene activity was assessed using quantitative reverse-transcription PCR, while receptor proteins were examined by flow cytometry and secreted inflammatory molecules were measured in the culture medium.
The most dramatic pattern emerged in pathways that detect nucleic acids, the molecular material of DNA and RNA. TLR9 is an intracellular receptor that recognizes DNA containing particular CpG motifs and can activate inflammatory transcription programs. One of its downstream regulators is IRF7, a transcription factor that helps drive type I interferon responses, while NF-κB, represented in the study by the NFKB1 gene, controls a broad range of inflammatory and survival-related genes. Following nanoparticle exposure, these systems showed little change during the first few hours, but their activity shifted later. TLR9 expression rose sharply in SET2 cells after 24 and 48 hours, reaching approximately 200- to 300-fold above control levels before falling toward baseline by 72 hours. The response did not clearly depend on whether the attached sequence targeted normal JAK2, mutant JAK2 or neither.
IRF7 displayed an even stronger mutation-associated response. In HEL cells, nanoparticles directed against JAK2V617F produced an approximately 20-fold increase in IRF7 expression at later time points. In SET2 cells, the increase approached 100-fold. These effects were much more pronounced than in the JAK2V617F-negative K562 line, suggesting that the mutant signaling environment altered how cells processed or responded to the nanoparticle-bound oligonucleotides. NFKB1 also increased after longer exposure, particularly in HEL and SET2 cells, where JAK2- and JAK2V617F-targeting particles produced roughly tenfold increases at 24 or 48 hours. K562 cells responded later and less consistently, reinforcing the idea that the nanoparticles were not acting through a single universal mechanism.
The second major surveillance system, known as cGAS-STING, responded in a similarly complicated fashion. cGAS detects DNA that appears in the cell’s cytoplasm, where it normally should not be. Once activated, it produces the small messenger molecule cyclic GMP-AMP, which binds to STING on the endoplasmic reticulum. STING then recruits the kinase TBK1, leading to activation of IRF3 and production of interferons and other inflammatory signals. In the experiments, cGAS expression generally increased after prolonged nanoparticle treatment, including in all three cell lines under at least some conditions. Yet STING did not rise in parallel. In K562 cells, for example, cGAS was strongly induced while STING showed little obvious response. This mismatch suggests that increasing the amount of cGAS does not necessarily activate the entire pathway; protein modification, degradation, trafficking or epigenetic repression may determine whether STING can transmit the signal.
The researchers also investigated RAGE, a receptor that can assist the delivery of extracellular nucleic acids into endosomes, the compartments where TLR9 is located. If the nanoparticles were activating TLR9 through a RAGE-dependent route, changes in RAGE protein might have been expected. Instead, flow-cytometry measurements in HEL cells found no significant changes in either surface or intracellular RAGE after short or long exposure to JAK2- or JAK2V617F-targeting particles. Intracellular TLR9 protein levels also remained largely unchanged, even when TLR9 messenger RNA increased. This distinction between RNA and protein is biologically important. Gene expression measured by PCR indicates that a transcript is more abundant, but it does not guarantee that more receptor will be produced. Messenger RNAs can be stabilized, trapped by RNA-binding proteins, transported differently or prevented from being efficiently translated. The result suggests that the delayed inflammatory response may be controlled downstream of transcription or through a pathway that does not require RAGE.
Cytokine measurements supplied a functional readout of the molecular changes. The investigators tested a broad panel that included interferons, tumour-necrosis factor, interleukins and the chemokine MCP-1, but IL-8, also called CXCL8, was the most notable signal. IL-8 levels increased in media from the JAK2V617F-positive HEL and SET2 cultures after extended treatment, with HEL cells showing a particularly strong response and a peak reported around 48 hours for some nanoparticle conditions. IL-8 attracts and activates immune cells and has been associated in myeloproliferative neoplasms with leukocytosis, thrombosis and bone-marrow fibrosis. Its induction therefore underscores both the therapeutic promise and the potential hazard of the approach: a particle intended to dampen pathological inflammation could, after a delay, stimulate inflammatory outputs depending on dose, sequence and cellular context.
The authors describe this behaviour as a biphasic response. In the short term, oligonucleotide-coated gold nanoparticles can suppress components of TLR9, IRF7 and related signaling networks, potentially reducing inflammatory activity. Over the following day or two, however, the same treatment can provoke increased expression of IRF7, TLR9, cGAS or NF-κB-associated genes, especially in cells carrying JAK2V617F. Such timing could reflect nanoparticle trafficking through endosomes, gradual release or processing of the attached oligonucleotides, delayed feedback from interferon signaling, or compensatory responses to attempted JAK2 suppression. The investigators emphasize that the effects were not always sequence-specific: scrambled nanoparticles sometimes produced comparable changes, raising the possibility that the gold core, the nucleic-acid coating or cellular uptake itself contributes to the response.
That complexity means the study is better viewed as a molecular map than as evidence of a ready-to-use treatment. The experiments used only three established cell lines, each with distinct origins and signaling abnormalities, and relied on a small number of replicate wells and PCR runs. The work did not demonstrate that the nanoparticles reduced cell proliferation, eliminated mutant clones or improved disease features in an organism. It also did not establish how the particles would distribute through the body, whether they would accumulate in the liver or spleen, how long they would persist, or whether they would trigger unwanted immune reactions. Before clinical testing, researchers will need to identify the precise mechanisms behind the early suppression and delayed activation, define safe exposure windows, test primary patient cells and evaluate toxicity in animal models.
Even so, the results highlight an emerging strategy in precision medicine: targeting not only an oncogenic mutation but also the inflammatory circuitry that sustains blood cancer. Because JAK2V617F-positive cells showed distinct IRF7 responses from mutation-negative cells, future nanoparticle designs might be tailored to particular genetic and disease subtypes. They could potentially be combined with existing JAK inhibitors, which block aberrant signaling but do not always eliminate the malignant clone or fully control inflammation. The immediate challenge is to turn the nanoparticles’ unpredictable timing into a controllable feature. If researchers can preserve the initial dampening effect while preventing the later inflammatory rebound, gold-bound oligonucleotides may become a versatile platform for modulating nucleic-acid sensing in myeloproliferative neoplasms and other inflammation-driven cancers.
